AXD2 Stock Overview A commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Heron Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Heron Therapeutics Historical stock prices Current Share Price US$1.47 52 Week High US$3.46 52 Week Low US$1.00 Beta 1.69 1 Month Change 46.75% 3 Month Change -15.82% 1 Year Change -5.83% 3 Year Change -83.28% 5 Year Change -93.26% Change since IPO -83.68%
Recent News & Updates
Forecast breakeven date pushed back to 2026 Nov 14
Third quarter 2024 earnings released: US$0.032 loss per share (vs US$0.17 loss in 3Q 2023) Nov 13 Heron Therapeutics, Inc. Revises Earnings Guidance for the Year 2024
Forecast breakeven date pushed back to 2026 Nov 13
Heron Therapeutics, Inc. Announces Appointment of Michael Kaseta to Board of Directors Nov 05
Heron Therapeutics, Inc. Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids Oct 11 See more updates
Forecast breakeven date pushed back to 2026 Nov 14
Third quarter 2024 earnings released: US$0.032 loss per share (vs US$0.17 loss in 3Q 2023) Nov 13 Heron Therapeutics, Inc. Revises Earnings Guidance for the Year 2024
Forecast breakeven date pushed back to 2026 Nov 13
Heron Therapeutics, Inc. Announces Appointment of Michael Kaseta to Board of Directors Nov 05
Heron Therapeutics, Inc. Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids Oct 11
Heron Therapeutics, Inc. Appoints Brett Fleshman as Chief Business Officer Sep 03
Second quarter 2024 earnings released: US$0.061 loss per share (vs US$0.35 loss in 2Q 2023) Aug 07
Heron Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 31
Heron Therapeutics, Inc. Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System Jul 15
Heron Therapeutics, Inc. Announces Acceptance of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle Jul 02
Heron Therapeutics, Inc. Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") May 30
Forecast breakeven date moved forward to 2025 May 09
First quarter 2024 earnings released: US$0.021 loss per share (vs US$0.28 loss in 1Q 2023) May 07
Heron Therapeutics, Inc., Annual General Meeting, Jun 13, 2024 May 01
Heron Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 27
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024 Mar 13
Full year 2023 earnings released: US$0.80 loss per share (vs US$1.67 loss in FY 2022) Mar 13
Heron Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024 Feb 29
Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures Jan 24
Forecast to breakeven in 2026 Dec 31
Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023 Dec 22
CEO & Director recently bought €127k worth of stock Nov 19
Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.38 loss in 3Q 2022) Nov 16
Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024 Nov 15
Heron Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Nov 08
New minor risk - Market cap size Oct 19
Second quarter 2023 earnings released: US$0.35 loss per share (vs US$0.55 loss in 2Q 2022) Aug 15
Heron Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 08
Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company Jul 25
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer Jun 24
Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Executive Vice President and Chief Development Officer Jun 14
Heron Therapeutics, Inc. Announces Management Changes Jun 13
First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.63 loss in 1Q 2022) May 12
Heron Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
No longer forecast to breakeven Mar 26
Full year 2022 earnings released: US$1.67 loss per share (vs US$2.24 loss in FY 2021) Mar 25
High number of new directors Mar 04
Rubric Capital Management Engages with Heron Therapeutics Feb 07
Forecast to breakeven in 2025 Jan 13
Heron Therapeutics, Inc. Provides Sales Guidance for the Full Year 2023 Jan 10
Forecast to breakeven in 2025 Dec 31
Heron Therapeutics, Inc. Announces the Submission of Supplemental New Drug Application for ZYNRELEF Dec 30
Third quarter 2022 earnings released: US$0.38 loss per share (vs US$0.51 loss in 3Q 2021) Nov 10
Heron Therapeutics, Inc. Provides Sales Guidance for the Year 2022 Nov 09
Heron Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Heron Therapeutics, Inc. Announces U.S. FDA Approval of APONVIE™ (HTX-019) for Prevention of Postoperative Nausea and Vomiting Sep 17 Heron Therapeutics, Inc. announced that it has received $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC Aug 12
Second quarter 2022 earnings released: US$0.55 loss per share (vs US$0.62 loss in 2Q 2021) Aug 10 Heron Therapeutics, Inc. announced that it expects to receive $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC and other investors Aug 10
Heron Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022 May 10
Heron Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022 May 04
Heron Therapeutics, Inc., Annual General Meeting, May 24, 2022 Apr 26 Heron Therapeutics, Inc. Does Not Provide Financial Guidance for the Full Year 2022
Heron Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022 Feb 24
Forecast to breakeven in 2024 Jan 01
Heron Therapeutics, Inc. Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF Dec 10
Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.64 loss in 3Q 2020) Nov 05
High number of new and inexperienced directors Nov 01
High number of new and inexperienced directors Oct 02
Second quarter 2021 earnings released: US$0.62 loss per share (vs US$0.61 loss in 2Q 2020) Aug 10
No longer forecast to breakeven Aug 10
Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™ Jul 23
Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF for the Management of Postoperative Pain for up to 72 Hours Jul 02
Heron Therapeutics, Inc. announced that it expects to receive $150 million in funding from Baker Bros. Advisors LP May 26
Heron Therapeutics Receives Approval from U.S. Food and Drug Administration for ZYNRELEF May 18
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours May 14
First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.57 loss in 1Q 2020) May 11
Heron Therapeutics, Inc. Provides Sales Guidance for the Full Year 2021 May 11
Revenue beats expectations Feb 25
Full year 2020 earnings released: US$2.50 loss per share (vs US$2.50 loss in FY 2019) Feb 25
Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery Jan 22
Heron Therapeutics, Inc. Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program Jan 12
New 90-day high: €16.85 Dec 23
Heron Therapeutics, Inc. Announces Resubmission of NDA to the U.S. Food and Drug Administration (FDA) for HTX-011 Nov 14
Revenue beats expectations Nov 06
Third quarter 2020 earnings released: US$0.64 loss per share Nov 06
New 90-day high: €14.60 Nov 06
Heron Therapeutics, Inc. Increases Earnings Guidance for the Full Year of 2020 Nov 06 Heron Therapeutics, Inc. Announces Retirement of Robert Hoffman as Chief Financial Officer, Effective October 16, 2020
Heron Therapeutics, Inc. Receives European Commission Authorization for Zynreleftm for the Treatment of Postoperative Pain Oct 05
GFS Chemicals, Inc. acquired Analytical Standards division of A.P. Pharma, Inc. Sep 26
Heron Therapeutics, Inc. Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery Sep 17
New 90-day low - €11.73 Aug 29
First half earnings released Aug 06 Shareholder Returns AXD2 DE Biotechs DE Market 7D -4.0% -2.9% -2.6% 1Y -5.8% -14.7% 6.9%
See full shareholder returns
Return vs Market: AXD2 underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is AXD2's price volatile compared to industry and market? AXD2 volatility AXD2 Average Weekly Movement 19.8% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: AXD2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AXD2's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Show more Heron Therapeutics, Inc. Fundamentals Summary How do Heron Therapeutics's earnings and revenue compare to its market cap? AXD2 fundamental statistics Market cap €230.31m Earnings (TTM ) -€26.80m Revenue (TTM ) €132.01m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AXD2 income statement (TTM ) Revenue US$137.74m Cost of Revenue US$72.38m Gross Profit US$65.36m Other Expenses US$93.33m Earnings -US$27.97m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.18 Gross Margin 47.45% Net Profit Margin -20.30% Debt/Equity Ratio -436.1%
How did AXD2 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 20:34 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Heron Therapeutics, Inc. is covered by 21 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Boran Wang Aegis Capital Corporation Tazeen Ahmad BofA Global Research Jonathan Aschoff Brean Capital
Show 18 more analysts 
